Harvest Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Harvest Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,816	Closed	-$228K	–	535
2020 Q2	$228K	Hold	1,816	–	–	0.02%	130
2020 Q1	$153K	Buy	1,816 +1,545	+570%	+$133K	0.02%	144
2019 Q4	$67K	Buy	+271	New	+$20.5K	0.01%	257

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Harvest Fund Management's BMRN Position: Q3 2020 in Review

Harvest Fund Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 1,816 shares — an estimated $228K sold.

Harvest Fund Management first reported a position in BMRN in Q4 2019 and held it in 3 quarters. The position peaked at $228K in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Harvest Fund Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Harvest Fund Management sold 1,816 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $228K.
Harvest Fund Management first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Harvest Fund Management's BioMarin Pharmaceuticals position peaked at $228K in Q2 2020.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Harvest Fund Management's 13F filing for Q3 2020, filed 4 Nov 2020.